Bormioli Pharma Addresses Drug Stability and Value-Added Medicines with Packaging Innovation

Revolutionary AccuRec Dual-Chamber Design Solves Two Industry
Challenges

PHILADELPHIA–(BUSINESS WIRE)–Bormioli
Pharma, one of the worldÔÇÖs leading glass and plastic packaging
manufacturers for the pharmaceutical sector, offers its innovative
dual-chamber AccuRec
system as a solution for unstable drug formulations and to deliver
value-added medicines.

AccuRec is a revolutionary dual-chamber packaging system that lets
patients reconstitute, in a few easy steps, an impressive range of oral
drug products right in the packaging container. Pre-dosed solvent and
drug powder are stored in separate chambers in a tamper-evident and
child-proof package; a simple twist releases the powder into the solvent
at time of dosing.

Drug Stability

The AccuRec system, and the precise, effective reconstitution it allows,
maximizes drug stability in reconstituted oral medicines by eliminating
the need to include excipients with the active ingredient. Excipients
are traditionally used in pharmaceuticals to make drugs more stable, but
this can contribute to additional adverse side effects from drug
toxicity, allergy, or intolerancei. AccuRec circumvents the
need for excipients because the chambers prevent active ingredients from
contacting and interacting with the solvent until the moment of
administration.

Until now, reconstitution at the time of dosing has been complex and
challenging for patients. The easy-to-use AccuRec system helps eliminate
the chance for human error by providing guided self-administration and
effective mixing of pre-dosed solvent and drug powder.

Value-Added Medicines

AccuRecÔÇÖs design makes it attractive for value-added medicines, which
are medicines based on known molecules that address health care needs
and deliver relevant improvements for patients, health care
professionals, and/or payersii. The value of existing
medicine can be enhanced through a broad range of processes, including
reformulation/repackaging.

Among the drivers for value-added medicines, patient non-adherence is
the top-most compliance concern, according to IQVIA Instituteiii.
Of the estimated avoidable costs, non-adherence (57%) far outpaced
delayed evidence-based treatment practice (13%), antibiotic misuse
(11%), and medication errors (9%) among total avoidable costs.
Value-added medicines are meant to deliver such benefits as greater
convenience, improved compliance, a better patient experience, safety,
better outcomes, or a more effective drug.

AccuRec is designed to improve the patient experience with easier,
simplified drug reconstitution. Turning a complex procedure like
reconstitution into an easy one can lead to better patient compliance
and offer pharmaceutical companies new ways to solve dosing and
compliance problems.

ÔÇ£We are very excited by the potential AccuRec offers to stakeholders
across healthcare, from payers to patients,ÔÇØ says Anna Malori, Business
Development Manager at Bormioli Pharma. ÔÇ£Its simplicity, accuracy, and
design make it a suitable solution for drug stability issues and an
attractive option for value-added medicines.ÔÇØ

Bormioli Pharma will exhibit AccuRec and a range of Type I Glass
containers in Booth 2001 at CPhI North America, April 24-26, 2018 at the
Pennsylvania Convention Center, Philadelphia, PA. The first at-scale
commercial rollout of the AccuRec system with a drug manufacturer is
expected in the second quarter of 2018.

About Bormioli Pharma

Bormioli Pharma exclusively serves the pharmaceutical and
biopharmaceutical market with integrated glass and plastic containers,
closures and accessories for packaging, using state-of-the-art materials
and technologies. This includes transparent and amber bottles in Type I,
II, and III glass for a range of dosage forms, as well as child-proof
and tamper-evident closures. These products are developed to guarantee
drug integrity and improve patient quality of life. Bormioli Pharma is
ISO 9001 and ISO 15378 (GMP) certified and registered with the main
international control organizations.

i Pifferi, G. and Restani, P. (2003) Il Farmaco 58
541-550.
ii Medicines for Europe http://www.medicinesforeurope.com/wp-content/uploads/2016/05/4-Value-Added-Medicines_On-Value-Added-Medicines-20160526_AB.pdf
iii
IQVIA European Thought Leadership; IQVIA Institute 2012 ÔÇ£Responsible Use
of MedicineÔÇØ

Contacts

Bormioli Pharma
Anna Malori, +39 334 6182183
[email protected]
or
Brandwidth
Solutions
Debra Harrsch, 215-997-8575
[email protected]